Item 8.01. Other Events.
On January 1, 2021, Bristol-Myers Squibb Company (the "Company") issued a press
release announcing that the Biologics License Application for lisocabtagene
maraleucel ("liso-cel") for the treatment of adults with relapsed or refractory
(R/R) large B-cell lymphoma after at least two prior therapies remains under
review by the U.S. Food and Drug Administration ("FDA") and that the Company has
not received a decision for this application. Since the FDA's approval of
liso-cel did not occur by December 31, 2020, one of the three required
milestones for payment of the Bristol-Myers Squibb Contingent Value Right
("CVR") was not met. As a result, on January 1, 2021, the Contingent Value
Rights Agreement, dated as of November 20, 2019 (the "CVR Agreement"), pursuant
to which the CVRs were issued, terminated automatically in accordance with its
terms and the CVRs are no longer eligible for payment under the CVR Agreement.
The CVRs will no longer trade on the NYSE.
A copy of the press release issued by the Company is attached as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is included as part of this Current Report on Form 8-K:
Exhibit
No. Description
99.1 Press release of Bristol-Myers Squibb Company dated January 1, 2021.
104 The cover page from this Current Report on Form 8-K formatted in Inline
XBRL (included as Exhibit 101).
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses